Central Pacific Bank Trust Division Buys New Holdings in Edwards Lifesciences Corporation $EW

Central Pacific Bank Trust Division purchased a new position in Edwards Lifesciences Corporation (NYSE:EW) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 9,088 shares of the medical research company’s stock, valued at approximately $775,000.

Other institutional investors have also added to or reduced their stakes in the company. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its position in shares of Edwards Lifesciences by 7.0% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock worth $10,719,000 after acquiring an additional 9,069 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Edwards Lifesciences by 13.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock valued at $6,706,000 after acquiring an additional 10,078 shares during the last quarter. Atlantic Union Bankshares Corp increased its holdings in Edwards Lifesciences by 2,240.9% in the 3rd quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock valued at $925,000 after acquiring an additional 11,384 shares during the last quarter. Washington Trust Advisors Inc. lifted its stake in Edwards Lifesciences by 15.6% in the 3rd quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock worth $10,156,000 after purchasing an additional 17,625 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp lifted its stake in Edwards Lifesciences by 97.3% in the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock worth $3,481,000 after purchasing an additional 21,950 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on EW. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, January 21st. Wells Fargo & Company boosted their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Royal Bank Of Canada increased their price target on Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, December 5th. TD Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. Finally, Canaccord Genuity Group set a $87.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, December 17th. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $96.14.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,371,239.08. The trade was a 24.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $85.38, for a total value of $87,002.22. Following the transaction, the vice president directly owned 33,934 shares in the company, valued at approximately $2,897,284.92. This represents a 2.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 61,718 shares of company stock worth $5,236,281. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $82.52 on Friday. The company’s 50-day moving average price is $82.23 and its 200-day moving average price is $81.64. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The company has a market cap of $47.92 billion, a PE ratio of 45.09, a price-to-earnings-growth ratio of 2.15 and a beta of 0.93. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The company had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same quarter in the prior year, the business posted $0.59 EPS. The company’s revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.